NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

Stock Information for NLS Pharmaceutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
NLS Pharmaceutics Announces Registered Direct Offering
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.